Does GEMTUZUMAB OZOGAMICIN Cause Second primary malignancy? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Second primary malignancy have been filed in association with GEMTUZUMAB OZOGAMICIN (Mylotarg). This represents 0.3% of all adverse event reports for GEMTUZUMAB OZOGAMICIN.
6
Reports of Second primary malignancy with GEMTUZUMAB OZOGAMICIN
0.3%
of all GEMTUZUMAB OZOGAMICIN reports
1
Deaths
1
Hospitalizations
How Dangerous Is Second primary malignancy From GEMTUZUMAB OZOGAMICIN?
Of the 6 reports, 1 (16.7%) resulted in death, 1 (16.7%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for GEMTUZUMAB OZOGAMICIN. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does GEMTUZUMAB OZOGAMICIN Cause?
Febrile neutropenia (412)
Pyrexia (138)
Sepsis (122)
Thrombocytopenia (117)
Venoocclusive liver disease (117)
Off label use (88)
Drug ineffective (87)
Death (81)
Bone marrow failure (80)
Neutropenia (68)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which GEMTUZUMAB OZOGAMICIN Alternatives Have Lower Second primary malignancy Risk?
GEMTUZUMAB OZOGAMICIN vs GEMZAR
GEMTUZUMAB OZOGAMICIN vs GENTAMICIN
GEMTUZUMAB OZOGAMICIN vs GEODON
GEMTUZUMAB OZOGAMICIN vs GILENYA
GEMTUZUMAB OZOGAMICIN vs GILOTRIF